Role of nitric oxide cGMP pathway in adrenomedullin-induced vasodilation in the rat

Citation
H. Hayakawa et al., Role of nitric oxide cGMP pathway in adrenomedullin-induced vasodilation in the rat, HYPERTENSIO, 33(2), 1999, pp. 689-693
Citations number
30
Categorie Soggetti
Cardiovascular & Respiratory Systems","Cardiovascular & Hematology Research
Journal title
HYPERTENSION
ISSN journal
0194911X → ACNP
Volume
33
Issue
2
Year of publication
1999
Pages
689 - 693
Database
ISI
SICI code
0194-911X(199902)33:2<689:RONOCP>2.0.ZU;2-H
Abstract
We previously reported that adrenomedullin (AM), a potent vasodilator pepti de discovered in pheochromocytoma cells, stimulates nitric oxide (NO) relea se in the rat kidney. To further investigate whether the NO-cGMP pathway is involved in the mechanisms of AM-induced vasodilation, we examined the eff ects of E-4021, a cGMP-specific phosphodiesterase inhibitor, on AM-induced vasorelaxation in aortic rings and perfused kidneys isolated from Wistar ra ts. We also measured NO release from the kidneys using a chemiluminescence assay. AM (10(-10) to 10(-7) mol/L) relaxed the aorta precontracted with ph enylephrine in a dose-dependent manner. Denudation of endothelium (E) atten uated the vasodilatory action of AM (10(-7) mol/L AM: intact (E+) -25.7 +/- 5.2% versus denuded (E-) -7.8 +/- 0.6%, P < 0.05), On the other hand, pret reatment with 10(-8) mol/L E-4021 augmented AM-induced vasorelaxation in th e intact aorta (-49.0 +/- 7.9%, P < 0.05) but not in the denuded one. E-402 1 also enhanced acetylcholine (ACh)-induced vasorelaxation in the rat intac t aorta (10(-7) mol/L ACh -36.6 +/- 8.4% versus 10(-8) mol/L E-4021 + 10(-7 ) mol/L ACh -62.7 +/- 3.1%, P < 0.05). In perfused kidneys, AM-induced vaso relaxation was also augmented by preincubation with E-4021 (10(-9) mol/L AM - 15.4 +/- 0.6% versus 10(-8) mol/L E-4021 + 10(-9) mol/L AM -23.6 +/- 1.2 %, P < 0.01). AM significantly increased NO release from rat kidneys (Delta NO: +11.3 +/- 0.8 fmol min(-1) g(-1) kidney at 10-9 mol/L AM), which was n ot affected by E-4021. E-4021 enhanced ACh-induced vasorelaxation (10(-9) m ol/L ACh -9.7 +/- 1.7% versus 10(-8) mol/L E-4021 + 10(-9) mol/L ACh -18.8 +/- 2.9%, P < 0.01) but did not affect ACh-induced NO release from the kidn eys. In the aorta and the kidney, 10(-4) moI/L of N-G-nitro-L-arginine meth yl ester, an NO synthase inhibitor, and 10(-5) mol/L of methylene blue, a g uanylate cyclase inhibitor, reduced the vasodilatory effect of AM. These re sults suggest that the NO-cGMP pathway is involved in the mechanism of AM-i nduced vasorelaxation, at least in the rat aorta and kidney.